WCLC 2025 - Posters & ePosters-P1.11.36 Strengthening Real World Evidence Generation Through an Expanding Multicenter Canadian Lung Cancer Registry

Pdf Summary

The Pan-Canadian Lung Cancer Observational Study (PALEOS) is a multicenter, ambispective registry established to generate robust real-world evidence (RWE) on lung cancer across Canada. Initiated in 2019, it collects detailed data from over 2,600 patients treated since 2000, representing about 30% of the Canadian population through six sites covering both urban and rural areas. PALEOS captures nearly 500 data points per patient, including demographics, clinical and molecular profiles, treatment pathways, healthcare utilization, and patient-reported outcomes.<br /><br />The study addresses the growing importance of real-world data (RWD) as a complement to traditional clinical trials, facilitating regulatory, funding, and clinical decision-making. It is particularly relevant for lung cancer, which comprises heterogeneous subgroups and complex treatment options, including chemotherapy, immunotherapy, and targeted therapies.<br /><br />Key findings show that over half of patients are diagnosed at stage IV, with a median overall survival varying significantly by stage—from 46.1 months in stage I to 9.7 months in stage IV. Treatment modalities reflect evolving care patterns, with first-line therapies including chemotherapy, immunotherapy, chemoimmunotherapy, and targeted agents. Molecular data demonstrate variable PD-L1 expression levels among patients. Follow-up durations differ by disease stage, averaging 18 months for stage I-III and 7.6 months for stage IV.<br /><br />PALEOS establishes a comprehensive platform facilitating examination of lung cancer's natural history, diagnostic and therapeutic strategies, outcomes, and quality of life measures in a representative Canadian population. Its structured registry supports health technology assessments, regulatory submissions, and funding decisions. Furthermore, it enables integration with international registries to advance collaborative lung cancer research.<br /><br />This initiative, led by Dr. Paul Wheatley-Price and collaborators across multiple Canadian cancer centers and supported by Pulse Infoframe, aims to strengthen data-driven, multidisciplinary lung cancer care through real-world insights.

Asset Subtitle

Paul Wheatley-Price

Meta Tag

Speaker Paul Wheatley-Price

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

Pan-Canadian Lung Cancer Observational Study

PALEOS

lung cancer

real-world evidence

real-world data

multicenter registry

treatment modalities

PD-L1 expression

overall survival

Canadian population